Novo Nordisk has announced that 13 abstracts from its research will be presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) in San Diego, California, from December 7 to 10, 2024. Of these, three…
The World Health Organization (WHO) convened the 40th meeting of the Emergency Committee under the International Health Regulations (2005) (IHR) on November 6, 2024. The committee, composed of members, advisers, and representatives from affected countries, reviewed data on wild poliovirus…
The National Home Infusion Association (NHIA) and Melinta Therapeutics, LLC, a biopharmaceutical company specializing in innovative therapies for acute and life-threatening conditions, are excited to announce Melinta’s membership in NHIA’s Future of Infusion Advisory Council (FIAC). This strategic advisory group…
Stallergenes Greer, a leading biopharmaceutical company specializing in allergen immunotherapy (AIT), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the extension of the indication…
Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical-stage botanical pharmaceutical company specializing in the development of unique botanical pharmaceutical and cosmeceutical products, has announced its financial results for the fiscal year ending July 31, 2024, as…
Nearly five years after the onset of COVID-19, a new report from the World Health Organization (WHO) reveals limited progress in closing critical gaps in infection prevention and control (IPC) to combat healthcare-associated infections (HAIs). HAIs, many of which can…
The Director-General of the World Health Organization (WHO) has released the report from the second meeting of the International Health Regulations (2005) (IHR) Emergency Committee regarding the mpox outbreak of 2024. The meeting took place on November 22, 2024, from…
Genentech, part of the Roche Group, has provided an update on the Phase III SKYSCRAPER-01 study, which evaluated the combination of tiragolumab with Tecentriq® (atezolizumab) compared to Tecentriq alone in patients with PD-L1-high, locally advanced or metastatic non-small cell lung…
Menarini Presents Data at SABCS 2024 Showcasing ORSERDU®’s Potential in ER+/HER2- Metastatic Breast Cancer The Menarini Group and its subsidiary, Stemline Therapeutics, are set to unveil new and expanded findings on ORSERDU® (elacestrant) at the 2024 San Antonio Breast Cancer…
Bicycle Therapeutics to Present Key Zelenectide Pevedotin Data at SABCS 2024 and Share Program Updates Bicycle Therapeutics plc (NASDAQ: BCYC), a company at the forefront of developing a novel therapeutic class based on its proprietary bicyclic peptide (Bicycle®) technology, will…
The Quadripartite organizations – the Food and Agriculture Organization of the United Nations (FAO), the United Nations Environment Programme (UNEP), the World Health Organization (WHO), and the World Organisation for Animal Health (WOAH) – have hailed the adoption of the…
Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced it has withdrawn its non-binding proposal to acquire Evotec SE (NASDAQ: EVO) at €11.00 per share in cash, representing a fully diluted equity value of €2.0 billion. Despite expressing strong interest in the merger,…
